Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Polaprezinc Granules

Approval Number

国药准字H20120091

Company吉林省博大伟业制药有限公司

Registration Date

September 2, 2022

Drug Information

Generic Name

聚普瑞锌颗粒

Trade Name

瑞莱生

Brand Name

瑞莱生

Dosage Form

颗粒剂

Strength

0.5g:75mg

Drug Type

化学药品

Registration Date

September 2, 2022

Company Information

Applicant Company

Company Name吉林省博大伟业制药有限公司

Company Address

辽源经济开发区财富大路158号

Manufacturing Company

Company Name吉林省博大伟业制药有限公司

Company Address

吉林省辽源经济开发区财富大路158号

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy